Rockefeller Capital Management
CCCC icon

Rockefeller Capital Management’s C4 Therapeutics CCCC Stock Holding History

Rockefeller Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,859
Closed -$69K – 2265
2022
Q4 		$69K Hold
11,859
– – ﹤0.01% 2223
2022
Q3 		$104K Hold
11,859
– – ﹤0.01% 1966
2022
Q2 		$89K Sell
11,859
-400
-3% -$3.52K ﹤0.01% 2003
2022
Q1 		$297K Buy
12,259
+11,859
+2,965% +$288K ﹤0.01% 1532
2021
Q4 		$12K Hold
400
– – ﹤0.01% 2879
2021
Q3 		$17K Buy
+400
New +$17.1K ﹤0.01% 2646

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rockefeller Capital Management's CCCC Position: Q1 2023 in Review

Rockefeller Capital Management sold out of C4 Therapeutics (CCCC) in Q1 2023, closing a stake of 11,859 shares — an estimated $69K sold.

Rockefeller Capital Management first reported a position in CCCC in Q3 2021 and held it in 6 quarters. The position peaked at $297K in Q1 2022. 120 funds tracked by Wall St. Rank hold CCCC as of Q1 2023.

  • Rockefeller Capital Management reported no remaining C4 Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 11,859 C4 Therapeutics shares in Q1 2023, an estimated $69K.
  • Rockefeller Capital Management first reported a position in C4 Therapeutics in Q3 2021 and held it in 6 quarters.
  • Rockefeller Capital Management's C4 Therapeutics position peaked at $297K in Q1 2022.
  • 120 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.